Crossmark

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

Published Online: 2022-04-29

Published Print: 2022-12

Authors

Ferrante, Nicola

Ritrovato, Daniela

Bitonti, Rossella

Furneri, Gianluca
License Information

Text and Data Mining valid from 2022-04-29

Version of Record valid from 2022-04-29
More Information

Article History

Received: 24 September 2021

Accepted: 20 April 2022

First Online: 29 April 2022

Declarations

:

: Not applicable.

: Not applicable.

: Furneri G. and Bitonti R.: consulting fees from Novartis Farma S.p.A. for analysis conduction.Ferrante N. and Ritrovato D.: employees of Novartis Farma S.p.A.No further CoI were declared.

Document is current